Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Cash flow is valuable, but it’s not everything - StockStory helps you identify the companies that truly put it to work. Keeping that in mind, here are three cash-producing companies to avoid and some better opportunities instead.
Sonos (SONO)
Trailing 12-Month Free Cash Flow Margin: 8.4%
A pioneer in connected home audio systems, Sonos (NASDAQ: SONO) offers a range of premium wireless speakers and sound systems.
Why Are We Out on SONO?
- Annual revenue declines of 2.6% over the last five years indicate problems with its market positioning
- Performance over the past five years shows each sale was less profitable as its earnings per share dropped by 11.5% annually, worse than its revenue
- Poor free cash flow margin of 6.3% for the last two years limits its freedom to invest in growth initiatives, execute share buybacks, or pay dividends
Sonos’s stock price of $16.94 implies a valuation ratio of 18.7x forward P/E. If you’re considering SONO for your portfolio, see our FREE research report to learn more.
Graco (GGG)
Trailing 12-Month Free Cash Flow Margin: 27.8%
Founded in 1926, Graco (NYSE: GGG) is an industrial company specializing in the development and manufacturing of fluid-handling systems and products.
Why Does GGG Give Us Pause?
- Muted 2.6% annual revenue growth over the last two years shows its demand lagged behind its industrials peers
- Earnings per share lagged its peers over the last two years as they only grew by 1.5% annually
- Eroding returns on capital suggest its historical profit centers are aging
At $78.38 per share, Graco trades at 22.8x forward P/E. Check out our free in-depth research report to learn more about why GGG doesn’t pass our bar.
Haemonetics (HAE)
Trailing 12-Month Free Cash Flow Margin: 21.1%
With roots dating back to 1971 and a mission to improve blood-related healthcare, Haemonetics (NYSE: HAE) provides specialized medical devices and software for blood collection, processing, and management across plasma centers, blood banks, and hospitals.
Why Is HAE Not Exciting?
- Flat sales over the last two years suggest it must find different ways to grow during this cycle
- Absence of organic revenue growth over the past two years suggests it may have to lean into acquisitions to drive its expansion
- Smaller revenue base of $1.35 billion means it hasn’t achieved the economies of scale that some industry juggernauts enjoy
Haemonetics is trading at $118.28 per share, or 18.4x forward P/E. Dive into our free research report to see why there are better opportunities than HAE.
Stocks We Like More
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.
